Printer Friendly

THE IMMUNE RESPONSE CORPORATION COMMENTS ON INTEREST IN PROGRESS ON HIV THERAPEUTIC VACCINE

        THE IMMUNE RESPONSE CORPORATION COMMENTS ON INTEREST
               IN PROGRESS ON HIV THERAPEUTIC VACCINE
    SAN DIEGO, Nov. 13 /PRNewswire/ -- The Immune Response Corporation (NASDAQ-NMS: IMNR) commented today on the recent interest in progress on HIV therapeutic vaccines in clinical studies and on yesterday's FDA Advisory Committee meeting discussing surrogate end- points in HIV therapies.
    In conjunction with Rhone-Poulenc Rorer Inc. (NYSE: RPR), Immune Response is conducting Phase II/III clinical trials on an HIV therapeutic vaccine.  These double-blind, placebo-controlled studies began in September 1990 and are scheduled to conclude in late 1992. To date, these and other studies indicate that the product appears safe and well tolerated.
    As Immune Response has previously stated, until these studies are completed, the company will not have any clear indication of whether or not the product appears to be effective in preventing the transition to AIDS in seropositive patients.  The studies are designed to capture changes in viral burden, T-cell counts and clinical end points.  Consistent with the opinions expressed in yesterday's FDA Advisory Committee meeting, all of these end-points should be considered in the evaluation and ultimate approval of immunotherapeutics.
    The Immune Response Corporation is a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection, which leads to AIDS, and for the treatment of certain autoimmune diseases, particularly rheumatoid arthritis, multiple sclerosis and insulin-dependent diabetes.
    -0-                   11/13/91
    /CONTACT:  Steven L. Basta, investor relations, or Charles J. Cashion, VP-Finance of The Immune Response Corporation, 619-431-7080/
    (IMNR RPR) CO:  The Immune Response Corporation; Rhone-Poulenc Rorer Inc. ST:  California IN:  MTC SU: CH-JL -- SD004 -- 4031 11/13/91 14:29 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 13, 1991
Words:272
Previous Article:BETZ LABORATORIES COMPLETES SALE OF COAL MINING CHEMICALS BUSINESS TO STOCKHAUSEN, INC.
Next Article:ENSCO AWARDED LONG-TERM CONTRACT FOR FOUR NEW BARGE DRILLING RIGS
Topics:


Related Articles
IMMUNE RESPONSE FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR NEW RHEUMATOID ARTHRITIS TREATMENT
IDEC PHARMACEUTICALS TO BEGIN HUMAN CLINICAL STUDY OF MONOCLONAL ANTIBODY-BASED THERAPEUTIC FOR TREATMENT OF HIV INFECTION
THE IMMUNE RESPONSE CORP., RHONE-POULENC RORER INC. AND PASTEUR MERIEUX CONNAUGHT GROUP ANNOUNCE DISCUSSIONS ON HIV MANUFACTURING JOINT VENTURE
THE IMMUNE RESPONSE CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END 1991 FINANCIAL RESULTS
THE IMMUNE RESPONSE CORPORATION PCR ASSAY CORRELATES VIRAL BURDEN WITH CLINICAL STAGE OF HIV INFECTION
THE IMMUNE RESPONSE CORP. CONFIRMS SCHEDULE FOR COMPLETION OF PHASE II/III CLINICAL TRIAL IN 1992
The Immune Response Corporation Publishes Additional Findings On T Cells Involved in Psoriasis
The UAB Research Foundation obtains United States patent.
Immune Response licenses Hybridon's AMPLIVAX vaccine adjuvant.
The Immune Response Corporation Licenses Hybridon's 2nd-Generation CpG DNA Adjuvant, AMPLIVAX(TM), for Use in Development of a Novel Vaccine for the...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters